In The Lancet Oncology, Xi-Chun Hu and colleagues1 report results of the CBCSG006 trial, which assessed the non-inferiority and possible superiority of a cisplatin plus gemcitabine regimen versus a paclitaxel plus gemcitabine regimen in patients with metastatic triple-negative breast cancer. Cancer therapeutics can generally be divided into so-called “smart” drugs and “dumb” drugs. The perfect smart cancer drug is tumourspecific, targeted, highly effective, and has little toxicity, whereas cytotoxic chemotherapeutics are generally the representative dumb drugs. However, evidence in triple-negative breast cancer calls this aphorism into question—chemotherapy could be targeted therapy. Even our dumb drugs might not be that dumb. The prototype targeted breast cancer therapy is endocrine therapy plus HER2-targeted drugs. However, chemotherapy cannot yet be removed from breast cancer therapy. HER2-targeted drugs